Revolution Medicines, Inc.

RVMD Net selling

CIK 0001628171 #590 in the set updated 21 Sep 2026

Bought (120 mo)

$134.50M

out of their own pocket, the only kind of buying there is

Sold (120 mo)

$441.00M

$43.01M on a plan · $165.93M straight out of an exercise

Sold at will

$232.07M

95 of 452 sales

Net

−$306.51M

−$97.57M against sales at will

By person

27 insiders · 503 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Schroeder Thilo

Director

$123.30M (37)

—

+$123.30M

760,869

0.3550%

$151.64M

—

Svennilson Peter

Director

—

$84.23M (18)

−$84.23M

1,795,538

0.8377%

$357.86M

−64.3%

GOLDSMITH MARK A

See Remarks

—

$81.07M (123) scheduled

−$81.07M

376,190

0.1755%

$74.98M

+15.0%

COLUMN GROUP III, LP entity

10% owner

—

$73.79M (2)

−$73.79M

4,580,206

2.14%

$912.85M

—

Third Rock Ventures II, L.P. entity

10% owner

—

$58.17M (4)

−$58.17M

0

0.0000%

$0.00

−100.0%

Kelsey Stephen Michael

See Remarks

—

$40.33M (84) scheduled

−$40.33M

286,307

0.1336%

$57.06M

+4.2%

Horn Margaret A

Chief Operating Officer

—

$37.83M (55) scheduled

−$37.83M

149,680

0.0698%

$29.83M

+6.5%

Cislini Jeff

SVP & General Counsel

—

$17.26M (43) scheduled

−$17.26M

52,541

0.0245%

$10.47M

+11.1%

Kim Lorence H.

Director

$1.00M (1)

$14.97M (14) scheduled

−$13.97M

1,191

0.0006%

$237.37K

—

Anders Jack

Chief Financial Officer

—

$10.76M (37) scheduled

−$10.76M

119,216

0.0556%

$23.76M

+1,764%

Flynn James E

10% owner

$10.20M (2)

—

+$10.20M

798,795

0.3727%

$159.20M

—

Mancini Anthony

See Remarks

—

$8.70M (19) scheduled

−$8.70M

42,116

0.0196%

$8.39M

−22.9%

Third Rock Ventures III, L.P. entity

10% owner

—

$8.50M (1)

−$8.50M

5,104,130

2.38%

$1.02B

—

Weber Barbara

Director

—

$1.90M (12) scheduled

−$1.90M

13,065

0.0061%

$2.60M

—

Patel Sushil

Director

—

$1.49M (12) scheduled

−$1.49M

21,656

0.0101%

$4.32M

—

Miller Vincent A.

Director

—

$613.66K (5)

−$613.66K

23,750

0.0111%

$4.73M

−23.0%

Wei Lin

Chief Medical Officer

—

$600.71K (4) scheduled

−$600.71K

101,366

0.0473%

$20.20M

−14.9%

ANDERSON ELIZABETH M

Director

—

$425.00K (3)

−$425.00K

24,406

0.0114%

$4.86M

+158.3%

Wang Xiaolin

See Remarks

—

$284.08K (9) scheduled

−$284.08K

116,063

0.0541%

$23.13M

+1,802%

Sandler Alan B.

Chief Development Officer

—

$67.94K (2) scheduled

−$67.94K

52,868

0.0247%

$10.54M

−0.6%

Exter Neil

Director

—

— (5)

$0.00

28,815

0.0134%

$5.74M

+44.1%

Borisy Alexis

Director

—

—

—

2,340,075

1.09%

$466.38M

+947.3%

Third Rock Ventures IV, L.P. entity

10% owner

—

—

—

1,419,900

0.6625%

$282.99M

—

Horning Sandra

Director

—

—

—

97,765

0.0456%

$19.48M

—

Borellini Flavia

Director

—

—

—

26,215

0.0122%

$5.22M

—

SCHMIDT ERIC THOMAS

Director

—

—

—

21,251

0.0099%

$4.24M

—

Clyburn Frank

Director

—

—

—

10,929

0.0051%

$2.18M

—

Individual transactions

2

Insider

Date

Role

Action

Shares

Price

Amount

Schroeder Thilo

5 Dec 2024

Director

Buy indirect

760,869

$46.00

$35.00M

Schroeder Thilo

5 Dec 2024

Director

Buy indirect

543,478

$46.00

$25.00M

Showing 250 of 503 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 367

Amendments (4/A) skipped 9

Filings about a different issuer 0

Unreadable filings 0

Joint filings 12

Sales on a Rule 10b5-1 plan 116

Sales straight out of an exercise 241

Sales at will 95

Transactions with no price 0

Shares from compensation/vesting 35,846,807

Sales filed before the plan box existed 81

History held since 14 Feb 2020